Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

@article{Ruszniewski2016PatientreportedOW,
  title={Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.},
  author={Philippe B Ruszniewski and Juan W Valle and C Lombard-bohas and Daniel J Cuthbertson and P Perros and Lubo{\vs} Holubec and Gianfranco delle Fave and Denis Smith and Patricia Niccoli and Pascal Maisonobe and Philippe Atlan and Martyn Evan Caplin},
  journal={Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver},
  year={2016},
  volume={48 5},
  pages={552-558}
}
BACKGROUND Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse. AIM To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome. METHODS This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome… CONTINUE READING
9 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…